Professor Gordan Vujanic

2017

• Vujanic, G., Apps, J. R., Moroz, V., Ceroni, F., Williams, R. D., Sebire, N. J. and Pritchard-Jones, K. 2017. Nephrogenic rests in wilms tumors treated with preoperative chemotherapy: The UK SIOP wilms tumor 2001 trial experience. Pediatric Blood and Cancer, pp. e26547. (10.1002/pbc.26547)

2016

• Chagtai, T. et al. 2016. Gain of 1q as a prognostic biomarker in Wilms Tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial: a SIOP renal tumours biology consortium study. Journal of Clinical Oncology 34(26), pp. 3195-3203. (10.1200/JCO.2015.66.0001)
• Gooskens, S. L. et al. 2016. The clinical phenotype ofYWHAE-NUTM2B/E positive pediatric clear cell sarcoma of the kidney. Genes, Chromosomes and Cancer 55(2), pp. 143-147. (10.1002/gcc.22320)

2015

• Pritchard-Jones, K. et al. 2015. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. The Lancet 386(9999), pp. 1156-1164. (10.1016/S0140-6736(14)62395-3)
• Pritchard-Jones, K. et al. 2015. Response to the letter to the editor: 1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk satisfaction in the SIOP2009/Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) trial. Genes, Chromosomes and Cancer 54(6), pp. 397-399. (10.1002/gcc.22250)
• van den Heuvel-Eibrink, M. et al. 2015. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). European Journal of Cancer 51(4), pp. 498-506. (10.1016/j.ejca.2014.12.011)
• Mavinkurve-Groothuis, A. M. C. et al. 2015. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG). Pediatric Blood and Cancer 62(4), pp. 598-602. (10.1002/pbc.25357)
• Charlton, J. et al. 2015. Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour. Genome Medicine 7, article number: 11. (10.1186/s13073-015-0136-4)
• Irtan, S. et al. 2015. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - The United Kingdom experience. European Journal of Cancer 51(2), pp. 225-232. (10.1016/j.ejca.2014.10.026)

2014

• Maschietto, M. et al. 2014. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS ONE 9(10), article number: e109924. (10.1371/journal.pone.0109924)
• Charlton, J. et al. 2014. Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood. Genome Biology 15(8) (10.1186/s13059-014-0434-y)
• Gooskens, S. et al. 2014. Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study. British Journal of Cancer 111, pp. 227-233. (10.1038/bjc.2014.291)

2013

• Furtwangler, R. et al. 2013. Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: A report of the SIOP Renal Tumour Study Group. European Journal of Cancer 49(16), pp. 3497-3506. (10.1016/j.ejca.2013.06.036)
• Popov, S. D., Vujanic, G., Sebire, N., Chagtai, T., Williams, R., Vaidya, S. and Pritchard-Jones, K. 2013. Bilateral Wilms tumor with TP53-related anaplasia. Pediatric and Developmental Pathology 16(3), pp. 217-223. (10.2350/12-08-1245-CR.1)
• J, W. et al. 2013. miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS ONE 8(1), article number: e53417. (10.1371/journal.pone.0053417)
• Israels, T. et al. 2013. SIOP PODC: Clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatric Blood & Cancer 60(1), pp. 5-11. (10.1002/pbc.24321)
• Segers, H. et al. 2013. Gain of 1q is a marker of poor prognosis in Wilms' tumors. Genes, Chromosomes and Cancer 52(11), pp. 1065-1074. (10.1002/gcc.22101)

2011

• Graf, N. et al. 2011. Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis? [Abstract]. Pediatric Blood and Cancer 57(5), pp. 741-742. (10.1002/pbc.23299)
• Pritchard-Jones, K. et al. 2011. Doxorubicin can be safely omitted from the treatment of stage II/III, intermediate risk histology wilms tumour: results of the siop wt 2001 randomised trial [Abstract]. Pediatric Blood and Cancer 57(5), pp. 741. (10.1002/pbc.23299)
• Slade, I. et al. 2011. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. Journal of Medical Genetics 48(4), pp. 273-278. (10.1136/jmg.2010.083790)

2010

• Williams, R. D. et al. 2010. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' Tumor. Clinical Cancer Research 16(7), pp. 2036-2045. (10.1158/1078-0432.CCR-09-2890)
• Pritchard-Jones, K. et al. 2010. Refining risk stratification for pretreated localised wilms tumours: the SIOP renal tumours srudy group experience [Abstract]. Pediatric Blood and Cancer 55(5), pp. 822. (10.1002/pbc.22779)
• Spreafico, F. et al. 2010. Late recurrences in Wilms tumour (wt) patients: an under-estimated problem? A retrospective cooperative prelimary view on aieop/siop/ukw protocols [Abstract]. Pediatric Blood and Cancer 55(5), pp. 821. (10.1002/pbc.22779)
• Segers, H. et al. 2010. Management of adults with Wilms tumor: recommendations based on international consensus [Abstract]. Pediatric Blood and Cancer 55(5), pp. 821. (10.1002/pbc.22779)
• Pritchard-Jones, K., Jitlal, M., Powis, M., Vujanic, G., Kelsey, A. and Mitchell, C. 2010. Should biopsy influence tumour staging in Wilms tumour? The UK experience [Abstract]. Pediatric Blood and Cancer 55(5), pp. 813. (10.1002/pbc.22779)
• Slade, I. et al. 2010. Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene. Journal of Medical Genetics 47(5), pp. 342-347. (10.1136/jmg.2009.072983)

2009

• Vuononvirta, R. et al. 2009. Expression of hepatocyte growth factor and its receptor Met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development. Clinical Cancer Research 15(8), pp. 2723-2730. (10.1158/1078-0432.CCR-08-1898)
• van den Heuvel-Eibrink, M. et al. 2009. Rhaboid tumours of the kidney (RTK) treated according to recent stop protocols, on behalf of the SIOP RTSG [Abstract]. Pediatric Blood and Cancer 53(5), pp. 753. (10.1002/pbc.22234)
• Stoneham, S. et al. 2009. Clear cell sarcoma of the kidney (CCSK) - combined 20 year experience of therapuetic outcomes from United Kingdom (UK) and France [Abstract]. Pediatric Blood and Cancer 53(5), pp. 753. (10.1002/pbc.22234)
• Messahel, B. et al. 2009. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a children's cancer and leukaemia group (CCLG) study. European Journal of Cancer 45(5), pp. 819-826. (10.1016/j.ejca.2009.01.005)

2008

• Vuononvirta, R. et al. 2008. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clinical Cancer Research 14(23), pp. 7635-7644. (10.1158/1078-0432.CCR-08-1620)
• Natrajan, R. et al. 2008. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours. Journal of Clinical Pathology 61(1), pp. 95-102. (10.1136/jcp.2007.047159)